Evotec SE Stock

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 11:35:46 2024-04-26 am EDT 5-day change 1st Jan Change
9.235 EUR +0.82% Intraday chart for Evotec SE -30.35% -56.60%
Sales 2024 * 884M 945M Sales 2025 * 1.06B 1.13B Capitalization 1.64B 1.75B
Net income 2024 * 32M 34.22M Net income 2025 * 97M 104M EV / Sales 2024 * 1.67 x
Net cash position 2024 * 161M 172M Net cash position 2025 * 166M 178M EV / Sales 2025 * 1.39 x
P/E ratio 2024 *
49.9 x
P/E ratio 2025 *
15.2 x
Employees 5,061
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.82%
1 week-31.34%
Current month-36.18%
1 month-31.49%
3 months-36.02%
6 months-43.40%
Current year-56.60%
More quotes
1 week
8.52
Extreme 8.52
14.22
1 month
8.52
Extreme 8.52
14.77
Current year
8.52
Extreme 8.52
21.42
1 year
8.52
Extreme 8.52
24.44
3 years
8.52
Extreme 8.52
45.83
5 years
8.52
Extreme 8.52
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Date Price Change Volume
24-04-26 9.235 +0.82% 4,259,285
24-04-25 9.16 -4.98% 6,588,216
24-04-24 9.64 -32.02% 21,191,170
24-04-23 14.18 +3.50% 654,746
24-04-22 13.7 +3.32% 725,516

Delayed Quote Xetra, April 26, 2024 at 11:35 am EDT

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.16 EUR
Average target price
24.7 EUR
Spread / Average Target
+169.65%
Consensus